Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells

This publication has 27 references indexed in Scilit:

• 701 ‘Tomudex’ (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): First results of a phase III study
  European Journal Of Cancer, 1995
• Folate-based thymidylate synthase inhibitors as anticancer drugs
  Annals of Oncology, 1995
• Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
  British Journal of Cancer, 1995
• Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells
  Cancer Chemotherapy and Pharmacology, 1994
• The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice
  Biochemical Pharmacology, 1993
• Enhancement of thymidylate synthase inhibition
  Current Opinion in Oncology, 1993
• The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
  Biochemical Pharmacology, 1991
• Modulation of anti-metabolite effects
  Biochemical Pharmacology, 1984
• Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid (CB3717), on human lymphoblastoid cells
  Biochemical Pharmacology, 1983
• Factors determining cell sensitivity to methotrexate: Studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines
  Published by Elsevier ,1974